MedTrace Logo

Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer

NCT02527317 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2018-02-09

No results posted yet for this study

Summary

This is a prospective, non-interventional, single arm study, which is examining doxorubicin and cyclophosphamide (AC) once every 2 weeks with lipegfilgrastim support in early breast cancer.

Conditions

Interventions

DRUG

Lipegfilgrastim

Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).

Sponsors & Collaborators

  • Beaumont Hospital

    lead OTHER

Principal Investigators

  • Patrick G Patrick, MD · Beaumont Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02527317 on ClinicalTrials.gov